MISSISSAUGA, Ontario , Jan. 30, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the executive management will participate in the 2018 BIO CEO and Investor Conference to be held February 12-13, 2018 in New York .
MISSISSAUGA, Ontario , Nov. 30, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that Scott J. Charles , Chief Financial Officer, is leaving the Company to pursue other opportunities, effective immediately.
-3Q 2017 Net Revenues of $24.3 Million ; Year-to-Date 2017 Net Revenues of $77.9 Million - -Implements Fiscal Improvements designed to Deliver Profitability, Support Growth & Extend Cash Runway- -Provides Updated 2017 Full-Year Guidance and Preliminary 2018 Full-Year Outlook- MISSISSAUGA,
-Executive Management to Host Conference Call on November 9, 2017 at 8:30 a.m. ET - MISSISSAUGA, Ontario , Oct. 25, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its third quarter 2017 financial results on Thursday, November 9, 2017
-2Q 2017 Net Revenues of $27.6 Million, a $15.0 Million Increase Compared to 2Q 2016- -First Half 2017 Net Revenues of $53.6 Million, a $33.0 Million Increase Compared to First Half 2016- MISSISSAUGA, Ontario , Aug. 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc.
-Executive Management to Host Conference Call on August 9, 2017 at 9:00 a.m. ET - MISSISSAUGA, Ontario , July 24, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its second quarter 2017 financial results on Wednesday, August 9, 2017 ,
-Patents Covering VIMOVO Infringed by Proposed Generics Developed by Dr. Reddy's Laboratories , Mylan, and Lupin- MISSISSAUGA, Ontario , June 27, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that the United States District
-Zontivity® is the Only Approved Protease-Activated Receptor-1 (PAR-1) Inhibitor, a Receptor for Thrombin on the Platelet Considered to be a Potent Platelet Activator- -75 Aralez Sales Representatives Now Targeting 12,000 Cardiologists, Primary Care Physicians and Vascular Surgeons- MISSISSAUGA,
MISSISSAUGA, Ontario , May 23, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the executive management will participate in the Jefferies Healthcare Conference to be held June 6-9, 2017 in New York .
